Margin Excellence for
Medical Devices
GPO contracts dictate 25–40% discounts. Consignment ties up capital for months. FDA qualification locks you into suppliers you cannot switch. Most of the margin levers are hidden in contract structures nobody has audited in years.
Medical devices is the one vertical where the margin problem is mostly a contract problem: GPO tiers, consignment terms, and reimbursement codes set the economics before a single unit ships. ADEXMA audits those structures with the Margin Architecture™ diagnostic calibrated to the regulatory and commercial realities of device manufacturers.
Four contract structures set device margins before a unit ships
Four structural forces that squeeze device margins in ways generic consulting cannot diagnose.
GPO contracts are eating your margin — and nobody has renegotiated the tiers
Vizient controls roughly half of hospital purchasing; Premier around 40%. Your GPO tier was set years ago on volume commitments you may or may not be hitting today. Every misaligned tier is 2–5% of margin given away for volume you are not getting.
Consignment inventory is a hidden cash trap
Implants sit in hospital field stock for 6–12 months at 18–30% annual carrying cost, with expiration waste on biologics and time-sensitive product. Your balance sheet carries all of it. The hospital carries zero risk.
FDA qualification cycles make you a captive buyer
Switching a supplier on a Class II device takes 6–12 months of requalification. Class III takes 12–18. Your procurement team cannot respond to cost pressure the way other manufacturers can — sourcing agility is structurally constrained, and your suppliers know it.
Reimbursement ceilings fix the price — but not your costs
DRG and APC codes determine what the hospital gets paid for a procedure, and that ceiling caps what they will pay you for the device inside it. Your costs keep rising. The reimbursement rate does not. The squeeze is structural, not cyclical.
The KPIs that matter for device manufacturers
Calibrated for the regulatory and commercial realities of medical devices — each with the diagnostic question we ask first.
| Metric | Target | Diagnostic question |
|---|---|---|
| GPO contract margin | >18% specialty · >8% commodity | When did you last audit tier alignment? |
| Consignment inventory turns | >3x implants · >6x consumables | What is your par level methodology? |
| Lot yield rate | >95% Class II · >90% Class III | Are yield losses priced into unit cost? |
| Sterilization cycle time | <10 days EtO · <5 days gamma | Is sterilization your longest lead time? |
| Hospital OTIF | >96% scheduled · >99% emergency | What does a missed delivery cost you? |
| Expiration waste rate | <2% of inventory value per year | Are you enforcing FEFO in the field? |
| Case fill rate | >98% scheduled · >95% emergency | Can you serve emergency cases reliably? |
Exhibit — device manufacturing KPI targets, ADEXMA diagnostic
Current macro read: semiconductor-adjacent supply chains are normalizing, but resin and packaging costs continue to rise against fixed reimbursement.
Where we focus for medical devices
Three practices, weighted for a business where the contract is the margin.
Pricing Excellence
GPO tier optimization
- GPO contract audit: are volume commitments aligned with actual purchases?
- Tier optimization across national GPO and direct contracts
- Procedure-based value pricing — implant, instruments, consumables, and field support as one bundle
- Outcome-based pricing models for premium products
Supply Chain Excellence
Consignment and sterilization
- Consignment par levels rebuilt from daily usage, replenishment lead time, and safety buffer — not history
- FEFO enforcement: 70% minimum shelf life on new consignment, 50% in the warehouse
- Sterilization capacity management — often the single longest lead-time element
- Field inventory visibility so expiring product moves before it writes off
Sales Excellence
Regulatory-aware selling
- Value articulation beyond price per unit — total procedure cost and clinical outcomes
- Surgeon preference alignment treated as commercial data, not anecdote
- 510(k) versus PMA pathway pricing implications built into the deal model
- Territory economics that carry field-support cost, not just quota
We understand your regulatory reality
The FDA pathway a device takes shapes its pricing power, its competitive moat, and its operational constraints.
Predicate device pathway (510(k))
Lower regulatory cost, but it limits differentiation claims. Pricing must justify itself against the existing predicate. The most common pathway for iterative improvements — and the hardest one to hold a premium on.
Pre-market approval (PMA)
The highest regulatory investment, and the strongest competitive moat. Clinical data earned through PMA is exactly what supports premium, outcome-based pricing — if the commercial team actually uses it.
Novel low-risk (De Novo)
Creates a new classification for genuinely novel devices. Where no predicate exists, the first mover sets the price anchor for the category — a pricing advantage most manufacturers under-exploit.
A GPO tier audit and consignment rebuild returned $4.5M in year one
An anonymized engagement. Real numbers.
A GPO tier audit at a device manufacturer found three of five tiers with a national GPO misaligned: the company was granting volume-tier discounts of 25–30% where actual purchase volumes warranted standard tiers of 15–20%. At the same time, consignment par levels had not been reviewed in four years — $8M of field inventory at 23% carrying cost and a 4.2% expiration waste rate.
We re-tiered the GPO contracts (worth roughly $2.1M a year), rebuilt par levels from actual daily usage and replenishment lead times — cutting field inventory 30% — and enforced FEFO discipline across the consignment base.
Total impact in year one
Working capital freed from consignment
Expiration waste rate, down from 4.2%
Exhibit — case pattern, medical device manufacturer
Other industries we serve
Same methodology. Industry-specific benchmarks, KPIs, and case patterns.
Find your hidden margin in medical devices
GPO tiers, consignment bloat, reimbursement ceilings — the margin is there. We work with device companies from $30M to $300M, with ISO 13485 and FDA regulatory context built into every recommendation. Start with the free Margin Scan — fifteen minutes, benchmarked against 1,231 scored companies.